Form 4: Corcept Therapeutics CBO Executes Stock Transfers
Statement of Changes in Beneficial Ownership
Chief Business Officer Gary Charles Robb reported a series of stock gifts and trust transfers involving Corcept Therapeutics common stock.
Summary
- Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, executed a series of stock transactions on May 13, 2026.
- The transactions involved the gifting of 5,300 shares from direct ownership and the transfer of 2,000 shares into custodial accounts for children.
- A total of 49,716 shares were transferred into the Gary Charles Robb TTE Robb Revocable Trust.
- Following these transactions, the reporting person maintains a direct beneficial ownership of 24,487 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the transactions are purely administrative and related to personal estate planning.
Positives
- The transactions reflect internal estate planning and gifting rather than open-market sales, which typically signals long-term commitment to the company.
Negatives
- None identified; the activity is consistent with routine personal financial management.
Risks
- None identified; this is a standard disclosure of beneficial ownership changes.
Future Outlook
No forward-looking guidance or operational outlook provided in this filing.
Industry Context
StockSavvy.ai notes that insider gifting and trust transfers are common practices among corporate executives for tax and estate planning purposes and generally do not indicate a change in sentiment regarding the company's future performance.
Comparison to Industry Standards
- The filing adheres to standard SEC Section 16(a) reporting requirements for executive officers.
Related Party Transactions
- Transfer of 49,716 shares to the Gary Charles Robb TTE Robb Revocable Trust.
Stakeholder Impact
- Minimal impact on shareholders as the transactions do not represent a divestment of interest in the company.
Key Dates
| Date | Description |
|---|---|
| 05/13/2026 | Date of the reported stock transactions. |
| 05/15/2026 | Date the Form 4 was filed with the SEC. |
Keywords
Corcept Therapeutics, CORT, Insider Trading, Form 4, Beneficial Ownership, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.